StockNews.com lowered shares of ContraFect (NASDAQ:CFRX – Get Rating) from a hold rating to a sell rating in a report released on Thursday.
Separately, Maxim Group raised ContraFect from a hold rating to a buy rating and set a $3.00 price target on the stock in a research note on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ContraFect presently has a consensus rating of Hold and an average target price of $180.75.
ContraFect Trading Down 5.2 %
Shares of NASDAQ CFRX opened at $1.47 on Thursday. The stock has a market cap of $2.31 million, a price-to-earnings ratio of -0.02 and a beta of 0.44. ContraFect has a 1-year low of $0.90 and a 1-year high of $363.20. The stock’s 50-day moving average is $1.67 and its 200 day moving average is $5.45.
Hedge Funds Weigh In On ContraFect
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of ContraFect by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock valued at $5,664,000 after buying an additional 11,064 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of ContraFect by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock valued at $1,486,000 after buying an additional 4,948 shares during the period. State Street Corp increased its stake in shares of ContraFect by 33.5% during the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock valued at $474,000 after buying an additional 32,563 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ContraFect by 62.9% during the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 43,564 shares during the period. Finally, Armistice Capital LLC purchased a new position in shares of ContraFect during the fourth quarter valued at approximately $393,000. 27.34% of the stock is owned by hedge funds and other institutional investors.
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.
- Get a free copy of the StockNews.com research report on ContraFect (CFRX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.